27 withdrawn. 27 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Withdrawn 27 |
| Phase 2 | 8 | Withdrawn 8 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC Chondroitin sulfate - Necrotizing Enterocolitis, Intestinal Ischemia | Phase 1 | Withdrawn | Indiana University | 2025-01-01 | 2025-10-10 | |
| A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis Microbiota suspension, Microbiota capsule, Placebo suspension - Ulcerative Colitis | Phase 1 | Withdrawn | Ferring Pharmaceuticals | 2024-03-12 | 2024-10-18 | |
| A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants GSK4381406, Placebo, Indomethacin - Colitis, Ulcerative | Phase 1 | Withdrawn | GlaxoSmithKline | 2023-10-31 | 2023-12-15 | |
| Non-operative vs. Operative Management of Acute Appendicitis in Vulnerable Patient Populations Laparoscopic appendectomy, Antibiotics (IV transitioned to oral) - Acute Appendicitis | Phase 1 | Withdrawn | University of Texas Southwestern Medical Center | 2023-10-01 | 2024-03-26 | |
| Randomized Trial Comparing Single vs. Maintenance Fecal Microbiota Transplant for Refractory Crohn's Disease in Children Fecal Microbiota Transplantation, Placebo - Crohn Disease | Phase 1 | Withdrawn | Stanford University | 2022-12-01 | 2023-04-14 | |
| A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease Foralumab - Crohn's Disease | Phase 1 | Withdrawn | Tiziana Life Sciences LTD | 2022-05-01 | 2022-10-20 | |
| Stem Cells for the Treatment of Pouchitis Mesenchymal Stem Cells (MSCs) - Pouchitis, Crohn's Disease | Phase 1 | Withdrawn | The Cleveland Clinic | 2022-04-01 | 2026-04-16 | |
| Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis BT-11 low, BT-11 high, Placebo - Eosinophilic Esophagitis | Phase 1 | Withdrawn | NImmune Biopharma | 2022-01-30 | 2023-06-07 | |
| Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's mesenchymal stem cells (MSCs) - Crohn's Disease, Fistula | Phase 1 | Withdrawn | The Cleveland Clinic | 2021-06-01 | 2026-04-15 | |
| Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease PF 06687234, [124I]IB PF 06687234 - Inflammatory Bowel Disease | Phase 1 | Withdrawn | Pfizer | 2020-12-07 | 2020-11-03 | |
| Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis Sulfur hexafluoride lipid-type A microspheres - Appendicitis Acute | Phase 1 | Withdrawn | Boston Children's Hospital | 2020-07-15 | 2020-07-17 | |
| AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) - Crohn's Disease, Fistulizing Crohn's Disease | Phase 1 | Withdrawn | Joshua M Hare | 2019-12-01 | 2026-01-27 | |
| Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas FE 203799 - Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult | Phase 1 / Phase 2 | Withdrawn | GlyPharma Therapeutics | 2018-09-01 | 2024-10-24 | |
| Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Non-narcotic pain control - Appendicitis, Pain, Postoperative | Phase 1 / Phase 2 | Withdrawn | University of Utah | 2017-09-05 | 2020-02-07 | |
| High-dose Cyclophosphamide for Severe Refractory Crohn Disease High-dose Cyclophosphamide - Crohn's Disease, Crohn Disease | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2015-03-01 | 2018-08-13 | |
| Contrast-Enhanced Ultrasound in Human Crohn's Disease Contrast Enhanced Ultrasound, Optison - Crohn's Disease | Phase 1 / Phase 2 | Withdrawn | University of Michigan | 2015-02-01 | 2015-06-15 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease E6011, Placebo - Crohn's Disease | Phase 1 | Withdrawn | Eisai Inc. | 2014-12-01 | 2015-11-05 | |
| Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy entolimod, intensity-modulated radiation therapy, cisplatin - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2014-01-01 | 2013-12-11 | |
| Ulcerative Colitis and Vitamin D Supplementation Vitamin D, placebo - Ulcerative Colitis | Phase 1 / Phase 2 | Withdrawn | University Hospital of North Norway | 2013-04-01 | 2015-06-02 | |
| Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis dexlansoprazole - Gastroesophageal Reflux Disease, Eosinophilic Esophagitis | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2012-03-01 | 2012-04-19 |
Showing 20 of 27. Sign in to see all of them.
Crohn Disease (10) · Colitis, Ulcerative (6) · Inflammatory Bowel Diseases (4) · Appendicitis (3) · Mucositis (3) · Eosinophilic Esophagitis (2) · Agnosia (1) · Deglutition Disorders (1) · Dysentery, Bacillary (1) · Enterocolitis, Necrotizing (1) · Fistula (1) · Gastroesophageal Reflux (1) · Hodgkin Disease (1) · Lymphoma (1) · Pain, Postoperative (1)
Digestive System Diseases (27) · Gastrointestinal Diseases (27) · Intestinal Diseases (22) · Inflammatory Bowel Diseases (13) · Colitis (6) · Colonic Diseases (6) · Infections (4) · Cecal Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Intraabdominal Infections (3) · Mouth Diseases (3) · Stomatognathic Diseases (3) · Eosinophilia (2)
Chondroitin Sulfates (2) · Anti-Bacterial Agents (1) · CBLB502 (1) · Capsule Endoscopy (1) · Cholecalciferol (1) · Cisplatin (1) · Cyclophosphamide (1) · Dexlansoprazole (1) · FS 069 (1) · Fecal Microbiota Transplantation (1) · Gangliosides (1) · Indomethacin (1) · Microbiota (1) · Radiotherapy, Intensity-Modulated (1) · Transcutaneous Electric Nerve Stimulation (1)
The Cleveland Clinic (2) · Boston Children's Hospital (1) · Eisai Inc. (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Federal University of Minas Gerais (1) · Ferring Pharmaceuticals (1) · GlaxoSmithKline (1) · GlyPharma Therapeutics (1) · Human Genome Sciences Inc. (1) · Indiana University (1) · Johns Hopkins University (1) · Joshua M Hare (1) · Mayo Clinic (1) · NImmune Biopharma (1) · Pfizer (1)
United States (11) · Brazil (1) · Canada (1) · Norway (1) · United Kingdom (1)
Alka Goyal, MD (1) · Amy L Lightner, MD (1) · Amy Lightner, MD (1) · Anurag Singh (1) · David Kerman, MD (1) · Dwight M Nance, Ph.D (1) · Elena Kamycheva, MD, PhD (1) · Germaine M Louis, M.D. (1) · Harriet Paltiel, MDCM (1) · Jeffrey A Alexander, MD (1) · Mark G. Lazarev, MD (1) · Michael T Clandinin, PhD (1) · Parvez S Mantry, MD (1)
2009 (1)